脾酪氨酸激酶与血管内皮生长因子受体2双靶点激酶抑制剂(OT202)治疗干眼的疗效与安全性:一项随机、溶媒对照2期试验
这项多中心、随机、双盲、溶媒对照2期试验评估了OT202(脾酪氨酸激酶与血管内皮生长因子受体2双靶点抑制剂)治疗中重度干眼病的疗效与安全性。患者按1:1:1随机接受0.5% OT202、1% OT202或溶媒每日3次治疗8周。1% OT202组第8周总角膜染色评分较基线下降显著优于溶媒组,且安全性耐受性良好;0.5% OT202组主要和次要结局均无显著变化。
要点
- 1% OT202组第8周总角膜染色评分较基线下降显著优于溶媒组(最小二乘均值差-0.82,95%CI -1.46至-0.18,P=0.0118)。
- 1% OT202组第8周眼表疾病指数评分下降显著优于溶媒组(治疗差-5.35,95%CI -10.16至-0.54,P=0.0296)。
- 0.5% OT202组主要和次要结局均无显著变化;最常见治疗相关不良事件为眼分泌物和眼瘙痒(各2.8%)。
核心结论
- 1% OT202在第8周较溶媒显著改善干眼病患者的总角膜染色评分,且安全性和耐受性良好。
- 结果提示1% OT202治疗干眼病具有潜力,并支持进一步评估。
研究设计与样本
- 多中心、随机、双盲、溶媒对照2期试验。
- 纳入病程至少6个月的中重度干眼病成人患者。
- 经过2周导入期后仍符合条件的患者按1:1:1随机接受0.5% OT202、1% OT202或OT202溶媒每日3次治疗8周。
主要发现
- 第8周1% OT202组总角膜染色评分较基线的最小二乘均值变化为-1.93±0.23,溶媒组为-1.11±0.23,治疗差-0.82(95%CI -1.46至-0.18,P=0.0118)。
- 第8周1% OT202组眼表疾病指数评分较基线的最小二乘均值变化为-16.25±1.77,溶媒组治疗差-5.35(95%CI -10.16至-0.54,P=0.0296)。
- 第8周1% OT202组中央角膜染色治疗差-0.20(95%CI -0.38至-0.02),鼻侧角膜染色治疗差-0.38(95%CI -0.66至-0.11)。
- 0.5% OT202组主要和次要结局均无显著变化。
- 最常见治疗相关不良事件为眼分泌物(2.8%)和眼瘙痒(2.8%)。
关键数值与推荐
- 主要终点为第8周总角膜染色评分较基线的变化。
- 次要终点包括第4周和第8周眼表疾病指数评分、视觉模拟量表评分、干眼症状评估评分、结膜充血评分、结膜染色评分、泪膜破裂时间、Schirmer I试验结果及各区域角膜染色评分的变化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of OT202 (Ocumension Therapeutics [Shanghai] Co, Ltd), a first-in-class, dual-target kinase inhibitor of spleen tyrosine kinase and vascular endothelial growth factor receptor 2, for treating moderate to severe dry eye disease (DED). DESIGN: Multicenter, randomized, double-masked, vehicle-controlled phase 2 trial. PARTICIPANTS: Adults with moderate to severe DED of at least 6 months' duration. METHODS: Patients who remained eligible after a 2-week run-in period were randomized 1:1:1 to receive 0.5% OT202, 1% OT202, or OT202 vehicle 3 times daily for 8 weeks. MAIN OUTCOME MEASURES: The primary end point was the change from baseline to week 8 in the total corneal staining score (TCSS). Secondary end points included changes in ocular surface disease index (OSDI) score, visual analog scale score, symptom assessment in dry eye score, conjunctival hyperemia score, conjunctival staining score, tear film breakup time, Schirmer I test results, and corneal staining score for each region at weeks 4 and 8. RESULTS: The 1% OT202 group demonstrated a significantly higher reduction in TCSS score from baseline (least-squares mean [LSM], -1.93 ± 0.23) compared with the vehicle group (LSM, -1.11 ± 0.23) at week 8 (treatment difference, -0.82; 95% confidence interval [CI], -1.46 to -0.18; P = 0.0118). Additionally, 1% OT202 demonstrated significantly greater reduction at week 8 in OSDI score (LSM, -16.25 ± 1.77) compared with the vehicle group (treatment difference, -5.35; 95% CI, -10.16 to -0.54; P = 0.0296), central corneal staining (treatment difference, -0.20; 95% CI, -0.38 to -0.02), and nasal corneal staining (-0.38; 95% CI, -0.66 to -0.11). However, the 0.5% OT202 group showed no significant changes in either primary or secondary outcomes. The most common treatment-related adverse events were eye discharge (2.8%) and eye pruritus (2.8%). CONCLUSIONS: One percent OT202 significantly improved TCSS scores at week 8 versus the vehicle in patients with DED. Additionally, OT202 exhibited favorable safety and tolerability. These results suggest 1% OT202's potential in treating DED and support further evaluation. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Wang H, Jin X, Zheng H, et al. Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye: A Randomized, Vehicle-Controlled Phase 2 Trial. Ophthalmology. 2025. PMID: 41192622. doi:10.1016/j.ophtha.2025.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。